HIV/AIDS profile and realities at a regional antiretroviral therapy clinic in Jerusalem: 12 years analysis

Evaluation of a novel in-house HIV-1 genotype drug resistance assay using clinical samples in China

Background

HIV drug resistance poses a major challenge for anti-retroviral treatment (ART) and the prevention and control of HIV epidemic.

Objective

The study aims to establish a novel in-house assay with high efficiency, named AP in- house method, that would be suitable for HIV-1 drug resistance detection in China.

Methods

An in-house HIV-1 genotyping method was used to sequence the partial pol gene from 60 clinical plasma samples; the results of our test were compared with a commercial ViroSeq HIV-1 genotyping system.

Results

Among sixty samples, 58(96.7%) were successfully amplified by AP in-house method, five of them harbored viral load below 1,000 copies/ml. The genotype distribution was 43.1% CRF07_BC (25/58), 39.7% CRF01_AE (23/58), 6.9% CRF55_01B (4/58), 5.2% subtype B (3/58) and 5.2% CRF08_BC (3/58). Compared with that of the ViroSeq system, the consistent rate of these nucleotides and amino acids obtained by AP in-house method was up to 99.5 ± 0.4% and 99.5 ± 0.4%, respectively. A total of 290 HIV-1 drug resistance mutations were identified by two methods, including 126 nucleoside reverse transcriptase inhibitors (NRTIs), 145 non-nucleoside reverse transcriptase inhibitors (NNRTIs) and 19 protease inhibitors (PIs) resistance mutations. Out of them, 94.1% (273/290) were completely concordant between the AP in-house method and the ViroSeq system.

Conclusion

Overall, the evaluation of AP in-house method provided comparable results to those of the ViroSeq system on diversified HIV-1 subtypes in China.

Infectious diseases among Ethiopian immigrants in Israel: a descriptive literature review

The mass immigration of Ethiopian Jews to Israel began in the 1980s. For most of these immigrants this was a time of sharp transition from a village life with very basic living conditions, in most cases without a regular supply of water, electricity, or healthcare services, to a modern Western urban society. The aim of this review was to search the medical literature on the characteristics of infectious diseases that are typical in Ethiopian immigrants (EI), using relevant keywords. There has been success in coping with diseases among EI, that are rare although recognized in Israel, in terms of screening and early identification. TB was common in Ethiopia over all the years of immigration to Israel. In contrast, HIV appeared in EI from 1999 when they had long stayovers in transition camps in Gondar and Addis Ababa where there was a high risk of infection with sexually transmitted diseases. There were often delays in diagnosing 'exotic' diseases that are endemic in Africa, but not well known in Israel, such as Onchocerciasis, Schistosomiasis, Strongyloidiasis, and Bartonella endocarditis, which cause severe morbidity and mortality among EI. We describe the effect on general morbidity in Israel, and how the healthcare services coped with these diseases, including obstacles, and failures and successes. In light of the ongoing immigration of African refugees to the United States and Europe, the Israeli experience can be of value to healthcare policy makers in developing strategies for the effective management by medical staff treating these immigrants.